ImmunityBio (IBRX)

• Market cap: $2.14B
• 1 day: 0.93%
• 5 days: -8.44%
• 1 month: -14.23%
• 3 months: -8.82%
• 6 months: 7.96%
• Year to date: -15.56%
• 1 year: -59.96%
• 5 years: -73.24%
• 10 years: -87.38%
• Sector: Healthcare
• Industry: Biotechnology

About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Employees: 685